Is this the long expected buy signal for Aurora?
Current prices under 8$ might be the entry price everyone has been waiting for.

Aurora Cannabis Inc. (ACB - Get Rating), based in Edmonton, Canada, is a vertically integrated manufacturer and seller of medical cannabis worldwide. While ACB's medical business in Canada and Europe had strong sales and growth in the third quarter of 2021, it suffered from headwinds from COVID-19 in other markets. The company's net sales in the cannabis segment decreased by $ 20.5 million ($ 16.43 million) to $ 18.0 million ($ 14.43 million) compared to the same period last year, primarily due to a decrease in orders with lower demand in the consumer cannabis market and a decrease in sales of cannabis derivatives. ACB's share price is down 15.5% year to date and 22.4% last month. With a closing price of $ 7.02 yesterday, ACB stock is trading 63% below its 52-week high of $ 18.98, which it hit on February 10th. Although the cannabis operator has made significant strides in diversifying its portfolio by launching new proprietary strains and expanding its presence in the UK's fast-growing medical cannabis market, it has struggled to achieve consistent sales growth. While investors remain bullish on the positive momentum in federal cannabis legalization, uncertainty over the Senate's stance on the Cannabis Administration and Opportunity Act, passed earlier last month, could lead to volatility in cannabis stocks in the coming months to lead. Therefore, ACB shares could continue to decline in the near future.





